This announcement is a separate document:
博安生物：自願性公告度拉糖肽注射液(BA5101)在美國獲批開展臨床試驗
BOAN BIOTECH: VOLUNTARY ANNOUNCEMENTAPPROVAL OBTAINED FOR INITIATING CLINICAL TRIALSFOR DULAGLUTIDE INJECTION (BA5101) IN THE U.S.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.